| Filed On | Filing |
|---|---|
| 23 Oct 2026 |
Form 4: Evans Daron, CFO
Gave 16,000 shares as a gift · Acquired 8,000 shares (Gift) |
| 21 Oct 2026 |
Proxy statement: annual meeting on December 2, 2026
CEO pay $5.7M, up 100% · say-on-pay vote |
| 14 Oct 2026 |
8-K: Regulation FD Disclosure
REDWOOD CITY, Calif., October 14, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced... |
| 07 Oct 2026 | PRE 14A |
| 05 Oct 2026 |
8-K: Regulation FD Disclosure
The Agency reiterated its commitment to addressing the unmet need for treatment |
| 24 Sep 2026 | 10-K |
| 24 Sep 2026 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., September 24, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), ... |
| 03 Sep 2026 |
Form 4: Karnawat Sunil Ratilal, Chief Commercial Officer
Gave up 2,267 shares to cover exercise price or tax ($10.2K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | SCHEDULE 13G |
| 07 Jul 2026 |
Form 4: Roberts Brian Kenneth, Chief Medical Officer
Gave up 3,062 shares to cover exercise price or tax ($15.3K) |
| 07 Jul 2026 |
Form 4: Elam Nevan C, Director
Gave up 8,004 shares to cover exercise price or tax ($39.9K) |
| 07 Jul 2026 |
Form 4: Evans Daron, CFO
Gave up 3,062 shares to cover exercise price or tax ($15.3K) |
| 02 Jun 2026 | 8-K: Regulation FD Disclosure |
| 15 May 2026 | SCHEDULE 13G |
| 12 May 2026 | 10-Q |
| 12 May 2026 | 8-K: Results of Operations and Financial Condition |
| 11 May 2026 | SCHEDULE 13G/A |
| 04 May 2026 | 8-K: Regulation FD Disclosure |
Loading...
